Techniques for brain imaging in vivo

NeuroMolecular Medicine

Volumn 6, Issue 1, 2004, Pages 65-78

  Garcia Alloza, Monica ^a   Bacskai, Brian J ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Alzheimer's disease; Imaging; MRI; Multiphoton; Neurology; PET; SPECT

Indexed keywords

3 METHYLSPIPERONE C 11; 8 CHLORO 2,3,4,5 TETRAHYDRO 3 METHYL 5 PHENYL 1H 3 BENZAZEPIN 7 OL HYDROGEN MALEATE; 8 CHLORO 2,3,4,5 TETRAHYDRO 3 METHYL 5 PHENYL 1H 3 BENZAZEPIN 7 OL HYDROGEN MALEATE C11; AMYLOID BETA PROTEIN; CARBON 11; CLOZAPINE; CONGO RED; DIZOCILPINE; DIZOCILPINE I 123; EPIDEPRIDE I 125; FLUORINE 18; FLUORODEOXYGLUCOSE F 18; FLUOROETHYLSPIPERONE F 18; HALOPERIDOL; HEXAMETHYLPROPYLENE AMINE OXIME TECHNETIUM TC 99M; ISOTOPE; MONOCRYSTALLINE IRON OXIDE NANOPARTICLE; N METHYLPIPERIDINE 4 YL ACETATE C 11; N SEC BUTYL 1 (2 CHLOROPHENYL) N METHYL 3 ISOQUINOLINECARBOXAMIDE; N SEC BUTYL 1 (2 CHLOROPHENYL) N METHYL 3 ISOQUINOLINECARBOXAMIDE I 123; N [2 [4 (2 METHOXYPHENYL) 1 PIPERAZINYL]ETHYL] N (2 PYRIDYL)CYCLOHEXANECARBOXAMIDE; OXYGEN 15; RACLOPRIDE C 11; RADIOPHARMACEUTICAL AGENT; THIOFLAVINE; UNCLASSIFIED DRUG; [2 [[2 [[[3 (4 CHLOROPHENYL) 8 METHYL 8 AZABICYCLO[3.2.1]OCT 2 YL]METHYL](2 MERCAPTOETHYL)AMINO]ETHYL]AMINO]ETHANETHIOLATO]OXOTECHNETIUM TC 99M;

ALZHEIMER DISEASE; BLOOD BRAIN BARRIER; BRAIN HEMORRHAGE; BRAIN TISSUE; BRAIN TOMOGRAPHY; CENTRAL NERVOUS SYSTEM DISEASE; CHROMOSOME 4; DIAGNOSTIC IMAGING; DIAGNOSTIC PROCEDURE; DOPAMINERGIC TRANSMISSION; EPILEPSY; FOLLOW UP; GENOTYPE; GRAY MATTER; HALLUCINATION; HUMAN; HUNTINGTON CHOREA; IN VIVO STUDY; INTERMETHOD COMPARISON; MAJOR DEPRESSION; MULTIPHOTON MICROSCOPY; NEAR INFRARED SPECTROSCOPY; NEUROIMAGING; NEUROLOGIC DISEASE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PARKINSON DISEASE; PHENOTYPE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; REVIEW; SCHIZOPHRENIA; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; STROKE;

ANIMALIA; RODENTIA;

EID: 25444438965     PISSN: 15351084     EISSN: None     Source Type: Journal    
DOI: 10.1385/nmm:6:1:065     Document Type: Review

References (101)

1. Agdeppa E. D., Kepe V., Liu J., et al. (2001) Binding characteristics of radiofluorinated 6-dialky-lamino-2-naphthylethylidene derivatives as positron emission tomography imaging probes for β-amyloid plaques in Alzheimer's disease. J. Neurosci. 21, RC189.
2. Almeida O. P., Burton E. J., Ferrier N., McKeith I. G., and O'Brien J. T. (2003) Depression with late onset is associated with right frontal lobe atrophy. Psychol. Med. 33, 675-681.
3. Andrews T. C., Weeks R. A., Turjanski N., et al. (1999) Huntington's disease progression: PET and clinical observations. Brain 122 (Pt. 12), 2353-2363.
4. Ashtari M., Greenwald B. S., Kramer-Ginsberg E., et al. (1999) Hippocampal/amygdala volumes in geriatric depression. Psychol. Med. 29, 629-638.
5. Bachoud-Levi A. C., Remy P., Nguyen J. P., et al. (2000) Motor and cognitive improvements in patients with Huntington's disease after neural transplantation. Lancet 356, 1975-1979.
6. Bacskai B. J., Hickey G. A., Skoch J., et al. (2003) Four-dimensional multiphoton imaging of brain entry, amyloid binding, and clearance of an amyloid-β ligand in transgenic mice. Proc. Natl. Acad. Sci. USA 100, 12,462-12,467.
7. Bacskai B. J., Kajdasz S. T., Christie R. H., et al. (2001) Imaging of amyloid-beta deposits in brains of living mice permits direct observation of clearance of plaques with immunotherapy. Nat. Med. 7, 369-372.
8. Bacskai B. J., Klunk W. E., Mathis C. A., and Hyman B. T. (2002) Imaging amyloid-β deposits in vivo. J. Cereb. Blood Flow Metab. 22, 1035-1041.
9. 11C]WAY-100635. Mol. Psychiatry 9, 386-392.
10. Bonne O., Gilboa A., Louzoun Y., et al. (2003) Cerebral blood flow in chronic symptomatic mild traumatic brain injury. Psychiatry Res. 124, 141-152.
11. Boxer A. L., Kramer J. H., Du A. T., et al. (2003) Focal right inferotemporal atrophy in AD with disproportionate visual constructive impairment. Neurology 61, 1485-1491.
12. Bremner J. D., Narayan M., Anderson E. R., Staib L. H., Miller H. L., and Charney D. S. (2000) Hippocampal volume reduction in major depression. Am. J. Psychiatry 157, 115-118.
13. Brown D. R., Wyper D. J., Owens J., et al. (1997) 123Iodo-MK-801: a spect agent for imaging the pattern and extent of glutamate (NMDA) receptor activation in Alzheimer's disease. J. Psychiatr. Res. 31, 605-619.
14. 18F-labeled 6-iodo-2-(4′-N,N-dimethylamino) phenylimidazo[1,2-a]pyridine derivatives as prospective radioligands for β-amyloid in Alzheimer's disease. J. Med. Chem. 47, 2208-2218.
15. Catafau A. M. (2001) Brain SPECT in clinical practice. Part I: perfusion. J. Nucl. Med. 42, 259-271.
16. Chatziioannou A. F., Cherry S. R., Shao Y., et al. (1999) Performance evaluation of microPET: a high-resolution lutetium oxyorthosilicate PET scanner for animal imaging. J. Nucl. Med. 40, 1164-1175.
17. Chatziioannou A., Tai Y. C., Doshi N., and Cherry S. R. (2001) Detector development for microPET II: a 1 microl resolution PET scanner for small animal imaging. Phys. Med. Biol. 46, 2899-2910.
18. Christie R., Yamada M., Moskowitz M., and Hyman B. (2001) Structural and functional disruption of vascular smooth muscle cells in a transgenic mouse model of amyloid angiopathy. Am. J. Pathol. 158, 1065-1071.
19. Denk W., Strickler J. H., and Webb W. W. (1990) Two-photon laser scanning fluorescence microscopy. Science 248, 73-76.
20. Dijkhuizen R. M. and Nicolay K. (2003) Magnetic resonance imaging in experimental models of brain disorders. J. Cereb. Blood Flow Metab. 23, 1383-1402.
21. Drevets W. C., Frank E., Price J. C., Kupfer D. J., Greer P. J., and Mathis C. (2000) Serotonin type-1A receptor imaging in depression. Nucl. Med. Biol. 27, 499-507.
22. Drevets W. C., Price J. L., Simpson J. R., Jr., et al. (1997) Subgenual prefrontal cortex abnormalities in mood disorders. Nature 386, 824-827.
23. Fiebach J. B., Schellinger P. D., Gass A., et al. (2004) Stroke magnetic resonance imaging is accurate in hyperacute intracerebral hemorrhage: a multi-center study on the validity of stroke imaging. Stroke 35, 502-506.
24. Fountoulakis K. N., Iacovides A., Gerasimou G., et al. (2004) The relationship of regional cerebral blood flow with subtypes of major depression. Prog. Neuropsychopharmacol. Biol. Psychiatry 28, 537-546.
25. Friedland R. P., Kalaria R., Berridge M., et al. (1997) Neuroimaging of vessel amyloid in Alzheimer's disease. Ann. NY Acad. Sci. 826, 242-247.
26. Frodl T., Meisenzahl E. M., Zetzsche T., et al. (2004) Hippocampal and amygdala changes in patients with major depressive disorder and healthy controls during a 1-year follow-up. J. Clin. Psychiatry 65, 492-499.
27. Gomez-Isla T., Price J. L., McKeel D. W., Jr., Morris J. C., Growdon J. H., and Hyman B. T. (1996) Profound loss of layer II entorhinal cortex neurons occurs in very mild Alzheimer's disease. J. Neurosci. 16, 4491-4500.
28. Grutzendler J., Kasthuri N., and Gan W. B. (2002) Long-term dendritic spine stability in the adult cortex. Nature 420, 812-816.
29. Guzman R., Lovblad K. O., Meyer M., Spenger C., Schroth G., and Widmer H. R. (2000) Imaging the rat brain on a 1.5 T clinical MR-scanner. J. Neurosci. Methods 97, 77-85.
30. Guzman R., Meyer M., Lovblad K. O., et al. (1999) Striatal grafts in a rat model of Huntington's disease: time course comparison of MRI and histology. Exp. Neurol. 156, 180-190.
31. Habraken J. B., de Bruin K., Shehata M., et al. (2001) Evaluation of high-resolution pinhole SPECT using a small rotating animal. J. Nucl. Med. 42, 1863-1869.
32. Hazlett E. A., Buchsbaum M. S., Hsieh P., et al. (2004) Regional glucose metabolism within cortical Brodmann areas in healthy individuals and autistic patients. Neuropsychobiology 49, 115-125.
33. 11C]MDL 100907: small animal PET and gene expression studies. Synapse 50, 251-260.
34. Huang S., Heikal A. A., and Webb W. W. (2002) Two-photon fluorescence spectroscopy and microscopy of NAD(P)H and flavoprotein. Biophys. J. 82, 2811-2825.
35. Huber S. J., Chakeres D. W., Paulson G. W., and Khanna R. (1990) Magnetic resonance imaging in Parkinson's disease. Arch. Neurol. 47, 735-737.
36. Hume S. P., Lammertsma A. A., Myers R., et al. (1996) The potential of high-resolution positron emission tomography to monitor striatal dopaminergic function in rat models of disease. J. Neurosci. Methods 67, 103-112.
37. Jack C. R., Jr., Shiung M. M., Gunter J. L., et al. (2004) Comparison of different MRI brain atrophy rate measures with clinical disease progression in AD. Neurology 62, 591-600.
38. Jacobs R. E. and Cherry S. R. (2001) Complementary emerging techniques: high-resolution PET and MRI. Curr. Opin. Neurobiol. 11, 621-629.
39. Joyal C. C., Pennanen C., Tiihonen E., Laakso M. P., Tiihonen J., and Aronen H. J. (2004) MRI volumetry of the vermis and the cerebellar hemispheres in men with schizophrenia. Psychiatry Res. 131, 115-124.
40. Karramkam M., Dolle F., Valette H., et al. (2002) Synthesis of a fluorine-18-labelled derivative of 6-nitroquipazine, as a radioligand for the in vivo serotonin transporter imaging with PET. Bioorg. Med. Chem. 10, 2611-2623.
41. Kasai K., Iwanami A., Yamasue H., Kuroki N., Nakagome K., and Fukuda M. (2002) Neuroanatomy and neurophysiology in schizophrenia. Neurosci. Res. 43, 93-110.
42. Kassubek J., Bernhard Landwehrmeyer G., Ecker D., et al. (2004a). Global cerebral atrophy in early stages of Huntington's disease: quantitative MRI study. Neuroreport 15, 363-365.
43. Kassubek J., Juengling F. D., Kioschies T., et al. (2004b) Topography of cerebral atrophy in early Huntington's disease: a voxel based morphometric MRI study. J. Neurol.Neurosurg. Psychiatry 75, 213-220.
44. Kavec M., Grohn O. H., Kettunen M. I., Silvennoinen M. J., Penttonen M., and Kauppinen R. A. (2001) Use of spin echo T(2) BOLD in assessment of cerebral misery perfusion at 1.5 T. Magma 12, 32-39.
45. Kessler R. M. (2003) Imaging methods for evaluating brain function in man. Neurobiol. Aging 24(Suppl.), S21-S35; discussion S37-S39.
46. Klunk W. E., Bacskai B. J., Mathis C. A., et al. (2002) Imaging Aβ plaques in living transgenic mice with multiphoton microscopy and methoxy-X04, a systemically administered Congo red derivative. J. Neuropathol. Exp. Neurol. 61, 797-805.
47. Klunk W. E., Engler H., Nordberg A., et al. (2004) Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Ann. Neurol. 55, 306-319.
48. Kung M. P., Hou C., Zhuang Z. P., Cross A. J., Maier D. L., and Kung H. F. (2004) Characterization of IMPY as a potential imaging agent for β-amyloid plaques in double transgenic PSAPP mice. Eur. J. Nucl. Med. Mol. Imaging. 8, 1136-1145.
49. Lahti A. C., Holcomb H. H., Weiler M. A., et al. (2004) Clozapine but nothaloperidol re-establishes normal task-activated rCBF patterns in schizophrenia within the anterior cingulate cortex. Neuropsychopharmacology 29, 171-178.
50. Lawrie S. M., Whalley H. C., Job D. E., and Johnstone E. C. (2003) Structural and functional abnormalities of the amygdala in schizophrenia. Ann. NY Acad. Sci. 985, 445-460.
51. Levene M. J., Dombeck D. A., Kasischke K. A., Molloy R. P., and Webb W. W. (2004) In vivo multiphoton microscopy of deep brain tissue. J. Neurophysiol. 91, 1908-1912.
52. Li F., Liu K. F., Silva M. D., et al. (2000) Transient and permanent resolution of ischemic lesions on diffusion-weighted imaging after brief periods of focal ischemia in rats: correlation with histopathology. Stroke 31, 946-954.
53. Ludemann L., Wurm R., and Zimmer C. (2002) Pharmacokinetic modeling of Gd-DTPA extravasation in brain tumors. Invest. Radiol. 37, 562-570.
54. Lythgoe M. F., Sibson N. R., and Harris N. G. (2003) Neuroimaging of animal models of brain disease. Br. Med. Bull. 65, 235-257.
55. Mamo D., Kapur S., Shammi C. M., et al. (2004) A PET study of dopamine D2 and serotonin 5-HT2 receptor occupancy in patients with schizophrenia treated with therapeutic doses of ziprasidone. Am. J. Psychiatry 161, 818-825.
56. Mascalchi M., Lolli F., Della Nave R., et al. (2004) Huntington disease: volumetric, diffusion-weighted, and magnetization transfer MR imaging of brain. Radiology 232, 867-873.
57. Mathis C. A., Bacskai B. J., Kajdasz S. T., et al. (2002) A lipophilic thioflavin-T derivative for positron emission tomography (PET) imaging of amyloid in brain. Bioorg. Med. Chem. Lett. 12, 295-298.
58. McLellan M. E., Kajdasz S. T., Hyman B. T., and Bacskai B. J. (2003) In vivo imaging of reactive oxygen species specifically associated with thioflavine S-positive amyloid plaques by multiphoton microscopy. J. Neurosci. 23, 2212-2217.
59. Mervaala E., Fohr J., Kononen M., et al. (2000) Quantitative MRI of the hippocampus and amygdala in severe depression. Psychol. Med. 30, 117-125.
60. Messa C., Colombo C., Moresco R. M., et al. (2003) 5-HT(2A) receptor binding is reduced in drug-naive and unchanged in SSRI-responder depressed patients compared to healthy controls: a PET study. Psychopharmacology (Berl) 167, 72-78.
61. Mizrahi A., Crowley J. C., Shtoyerman E., and Katz L. C. (2004) High-resolution in vivo imaging of hippocampal dendrites and spines. J. Neurosci. 24, 3147-3151.
62. Mortimer J. A., Gosche K. M., Riley K. P., Markesbery W. R., and Snowdon D. A. (2004) Delayed recall, hippocampal volume and Alzheimer neuropathology: findings from the Nun Study. Neurology 62, 428-432.
63. Moseley M. E., Kucharczyk J., Mintorovitch J., et al. (1990) Diffusion-weighted MR imaging of acute stroke: correlation with T2-weighted and magnetic susceptibility-enhanced MR imaging in cats. AJNR Am. J. Neuroradiol. 11, 423-429.
64. Myers R., and Hume S. (2002) Small animal PET. Eur. Neuropsychopharmacol. 12, 545-555.
65. Namba H., Fukushi K., Nagatsuka S., et al. (2002) Positron emission tomography: quantitative measurement of brain acetylcholinesterase activity using radiolabeled substrates. Methods 27, 242-250.
66. Nikolaus S., Larisch R., Beu M., Forutan F., Vosberg H., and Muller-Gartner H. W. (2003) Bilateral increase in striatal dopamine D2 receptor density in the 6-hydroxydopamine-lesioned rat: a serial in vivo investigation with small animal PET. Eur. J. Nucl. Med. Mol. Imaging 30, 390-395.
67. Nopoulos P. C., Ceilley J. W., Gailis E. A., and Andreasen N. C. (2001) An MRI study of midbrain morphology in patients with schizophrenia: relationship to psychosis, neuroleptics, and cerebellar neural circuitry. Biol. Psychiatry 49, 13-19.
68. Okubo Y., Suhara T., Suzuki K., et al. (1997) Decreased prefrontal dopamine D1 receptors in schizophrenia revealed by PET. Nature 385, 634-636.
69. Okubo Y., Suhara T., Suzuki K., et al. (2000) Serotonin 5-HT2 receptors in schizophrenic patients studied by positron emission tomography. Life Sci. 66, 2455-2464.
70. Pavese N., Andrews T. C., Brooks D. J., et al. (2003) Progressive striatal and cortical dopamine receptor dysfunction in Huntington's disease: a PET study. Brain 126, 1127-1135.
71. Piccini P., Lindvall O., Bjorklund A., et al. (2000) Delayed recovery of movement-related cortical function in Parkinson's disease after striatal dopaminergic grafts. Ann. Neurol. 48, 689-695.
72. Pirker W., Asenbaum S., Wenger S., et al. (1997) Iodine-123-epidepride- SPECT: studies in Parkinson's disease, multiple system atrophy and Huntington's disease. J. Nucl. Med. 38, 1711-1717.
73. Poduslo J. F., Curran G. L., Peterson J. A., et al. (2004) Design and chemical synthesis of a magnetic resonance contrast agent with enhanced in vitro binding, high blood-brain barrier permeability, and in vivo targeting to Alzheimer's disease amyloid plaques. Biochemistry 43, 6064-6075.
74. Poduslo J. F., Wengenack T. M., Curran G. L., et al. (2002) Molecular targeting of Alzheimer's amyloid plaques for contrast-enhanced magnetic resonance imaging. Neurobiol. Dis. 11, 315-329.
75. Pouratian N., Sheth S. A., Martin N. A., and Toga A. W. (2003). Shedding light on brain mapping: advances in human optical imaging. Trends Neurosci. 26, 277-282.
76. Pouratian N., Sicotte N., Rex D., et al. (2002) Spatial/temporal correlation of BOLD and optical intrinsic signals in humans. Magn. Reson. Med. 47, 766-776.
77. Pujol J., Junque C., Vendrell P., Grau J. M., and Capdevila A. (1992) Reduction of the substantia nigra width and motor decline in aging and Parkinson's disease. Arch. Neurol. 49, 1119-1122.
78. Rapoport J. L., Castellanos F. X., Gogate N., Janson K., Kohler S., and Nelson P. (2001) Imaging normal and abnormal brain development: new perspectives for child psychiatry. Aust. NZJ Psychiatry 35, 272-281.
79. Scheltens P. and Korf E. S. (2000) Contribution of neuroimaging in the diagnosis of Alzheimer's disease and other dementias. Curr. Opin. Neurol. 13, 391-396.
80. Sheline Y. I. (2000) 3D MRI studies of neuroanatomic changes in unipolar major depression: the role of stress and medical comorbidity. Biol. Psychiatry 48, 791-800.
81. Schindler M. K., Wang L., Selemon L. D., Goldman-Rakic P. S., Rakic P., and Csernansky J. G. (2002) Abnormalities of thalamic volume and shape detected in fetally irradiated rhesus monkeys with high dimensional brain mapping. Biol. Psychiatry 51, 827-837.
82. Shoghi-Jadid K., Small G. W., Agdeppa E. D., et al. (2002) Localization of neurofibrillary tangles and β-amyloid plaques in the brains of living patients with Alzheimer disease. Am. J. Geriatr. Psychiatry 10, 24-35.
83. Silverman D. H., Small G. W., Chang C. Y., et al. (2001). Positron emission tomography in evaluation of dementia: regional brain metabolism and long-term outcome. JAMA 286, 2120-2127.
84. Simmons N. E., Helm G. A., Cail W. S., Bennett J. P., and Jane J. A. (1994) Magnetic resonance imaging of neuronal grafts in the primate. Exp. Neurol. 125, 52-57.
85. Skoch J., Dunn A., Hyman B. T., and Bacskai B. J. Development of an optical approach for non-invasive imaging of Alzheimer's disease pathology. J. Biomed. Opt., in press.
86. Soderstrom H., Hultin L., Tullberg M., Wikkelso C., Ekholm S., and Forsman A. (2002) Reduced frontotemporal perfusion in psychopathic personality. Psychiatry Res. 114, 81-94.
87. Sohmiya M., Tanaka M., Aihara Y., and Okamoto K. (2004) Structural changes in the midbrain with aging and Parkinson's disease: an MRI study. Neurobiol. Aging 25, 449-453.
88. 11C]RGH-1756 in the monkey brain. Neurochem. Int. 45, 609-617.
89. Stevens H., Jansen H. M., De Reuck J., et al. (1999) 55Cobalt (Co) as a PET-tracer in stroke, compared with blood flow, oxygen metabolism, blood volume and gadolinium-MRI. J. Neurol. Sci. 171, 11-18.
90. Strangman G., Culver J. P., Thompson J. H., and Boas D. A. (2002) A quantitative comparison of simultaneous BOLD fMRI and NIRS recordings during functional brain activation. Neuroimage 17, 719-731.
91. Thanos P. -K., Taintor N. B., Alexoff D., et al. (2002) In vivo comparative imaging of dopamine D2 knockout and wild-type mice with 11C-raclopride and microPET. J. Nucl. Med. 43, 1570-1577.
92. 3 regenerative amplifier. Opt. Lett. 28, 1022-1024.
93. Trachtenberg J. T., Chen B. E., Knott G. W., et al. (2002) Long-term in vivo imaging of experience-dependent synaptic plasticity in adult cortex. Nature 420, 788-794.
94. Vakili K., Pillay S. S., Lafer B., et al. (2000) Hippocampal volume in primary unipolar major depression: a magnetic resonance imaging study. Biol. Psychiatry 47, 1087-1090.
95. Versijpt J. J., Dumont F., Van Laere K. J., et al. (2003) Assessment of neuroinflammation and microglial activation in Alzheimer's disease with radiolabelled PK11195 and single photon emission computed tomography. A pilot study. Eur. Neurol. 50, 39-47.
96. Volkow N. D., Chang L., Wang G. J., et al. (2001) Loss of dopamine transporters in methamphetamine abusers recovers with protracted abstinence. J. Neurosci. 21, 9414-9418.
97. von Horsten S., Schmitt I., Nguyen H. P., et al. (2003) Transgenic rat model of Huntington's disease. Hum. Mol. Genet. 12, 617-624.
98. Wadghiri Y. Z., Sigurdsson E. M., Sadowski M., et al. (2003) Detection of Alzheimer's amyloid in transgenic mice using magnetic resonance microimaging. Magn. Reson. Med. 50, 293-302.
99. 99mTc-TRODAT-1 SPECT imaging in differentiating patients with idiopathic Parkinson's disease from healthy subjects. J. Nucl. Med. 45, 393-401.
100. Wilcox J., Tsuang M. T., Ledger E., Algeo J., and Schnurr T. (2002) Brain perfusion in autism varies with age. Neuropsychobiology 46, 13-16.
101. Wrynn A. S., Mac Sweeney C. P., Franconi F., et al. (2000) An in-vivo magnetic resonance imaging study of the olfactory bulbectomized rat model of depression. Brain Res. 879, 193-199.